Vidac Pharma receives US patent office Notice of Allowance for crucial compounds in its cancer drug candidates
03 juin 2024 01h30 HE
|
Vidac Pharma Holding PLC
London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel...
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis
10 avr. 2024 07h00 HE
|
Sitryx Therapeutics
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis First program from proprietary pipeline of novel immunometabolism-targeting therapies...
Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development
04 mars 2024 07h00 HE
|
Sitryx Therapeutics
Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development Ben Stephens brings seasoned operational and...
Vidac Pharma présente des résultats in vitro démontrant la compatibilité de VDA 1275 avec des agents chimiothérapeutiques classiques
29 nov. 2023 01h00 HE
|
Vidac Pharma Holding PLC
Un nouveau régulateur du métabolisme des cellules cancéreuses bientôt à l’étude en vue d’une obtention d’une autorisation de mise sur le marché (IND) Londres (Royaume-Uni), Rehovot (Israël), 29...
Vidac Pharma reports in vitro results showing VDA-1275 compatible with classical chemotherapy
29 nov. 2023 01h00 HE
|
Vidac Pharma Holding PLC
Novel cancer cell metabolism regulator to progress into IND enabling studies London (UK), Rehovot (Israel), 29 November 2023, 7:00 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G;...
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue
01 déc. 2020 12h05 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it...
Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
06 août 2020 09h00 HE
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...